GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Pre-Tax Income

CHMMF (Chimeric Therapeutics) Pre-Tax Income : $-8.30 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Chimeric Therapeutics's pretax income for the six months ended in Dec. 2023 was $1.59 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.30 Mil. Chimeric Therapeutics's pretax margin was %.


Chimeric Therapeutics Pre-Tax Income Historical Data

The historical data trend for Chimeric Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Pre-Tax Income Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Pre-Tax Income
-11.56 -11.06 -17.05 -8.31

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Pre-Tax Income Get a 7-Day Free Trial -4.25 -7.86 -9.24 1.59 -9.89

Competitive Comparison of Chimeric Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Chimeric Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimeric Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Pre-Tax Income falls into.



Chimeric Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Chimeric Therapeutics's Pretax Income for the fiscal year that ended in Jun. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-13.958+5.784+-0.22+0.08+0.0010000000000012
=-8.31

Chimeric Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-6.05+7.827+-0.222+0.032+2.2204460492503E-16
=1.59

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics  (OTCPK:CHMMF) Pre-Tax Income Explanation

Chimeric Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=1.587/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research 02-13-2024